Intersection · Evidence × surrogate endpoints

Evidence topics tagged surrogate endpoints

Topics in Evidence carrying the tag surrogate endpoints. A measurable stand-in for the outcome that actually matters.

24 topics

Topic	Participants	Replies	Views	Activity
What a statistical analysis plan adds that the paper does not open label discontinuation & dropout randomised trial surrogate endpoints Solved What a statistical analysis plan adds that the paper does not — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SCALE ( N Engl J Med , 2015) cited in support…		2	6.6k	10h
Second pass at: Reading a trial's population section before its results open label intention to treat estimand surrogate endpoints Solved Second pass at: Reading a trial's population section before its results Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in…		4	9.5k	10h
Primary endpoint hierarchies and why order matters — one year on surrogate endpoints discontinuation & dropout estimand randomised trial Solved On the subject in the title: Primary endpoint hierarchies and why order matters — one year on Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with SURPASS-2 ( N Engl J Med ,…	+56	61	37k	11h
Composite endpoints and the component doing the work randomised trial surrogate endpoints open label discontinuation & dropout Solved Under review Composite endpoints and the component doing the work Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I do…	+3	7	33k	13h
Subgroup analyses: pre-specified versus discovered randomised trial intention to treat surrogate endpoints estimand Subgroup analyses: pre-specified versus discovered — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURPASS-4 ( Lancet , 2021) and finding the…		2	27k	1d
Interim analyses and stopping rules intention to treat surrogate endpoints open label discontinuation & dropout Interim analyses and stopping rules Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in support of a claim I do not think…	+25	29	35k	16d
Run-in periods and the population they select surrogate endpoints discontinuation & dropout estimand randomised trial On the subject in the title: Run-in periods and the population they select Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before posting; the…	+130	142	7.3k	1mo
Reading a trial's population section before its results estimand surrogate endpoints discontinuation & dropout randomised trial Solved On the subject in the title: Reading a trial's population section before its results Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of a claim I do not think it…	+91	109	22k	2mo
Adjudicated events and why the definition matters estimand intention to treat discontinuation & dropout surrogate endpoints Under review On the subject in the title: Adjudicated events and why the definition matters Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before posting; the…		2	4.5k	2mo
Revisiting: Primary endpoint hierarchies and why order matters estimand surrogate endpoints discontinuation & dropout intention to treat Posting this under the heading it deserves: Revisiting: Primary endpoint hierarchies and why order matters Everything below is what sits behind that. Comparing SURMOUNT-4 ( JAMA , 2024) with SURPASS-2 ( N…	+21	25	46k	3mo
[2026 update] Composite endpoints and the component doing the work surrogate endpoints discontinuation & dropout estimand On the subject in the title: Composite endpoints and the component doing the work Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SURPASS-4 ( Lancet , 2021) and…	+76	87	994	3mo
Follow-up: What a statistical analysis plan adds that the paper does not randomised trial estimand open label surrogate endpoints What a statistical analysis plan adds that the paper does not I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in…		2	7.2k	3mo
Run-in periods and the population they select — the long version randomised trial estimand intention to treat surrogate endpoints Run-in periods and the population they select — the long version Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl J Med , 2016). Please read…		2	8.9k	4mo
[2026 update] Reading a supplementary appendix and finding the interesting part estimand intention to treat open label surrogate endpoints On the subject in the title: Reading a supplementary appendix and finding the interesting part Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with FLOW ( N Engl J Med , 2024)…	+39	44	8.2k	5mo
Non-inferiority margins: how they are chosen and how they are abused open label surrogate endpoints estimand intention to treat Posting this under the heading it deserves: Non-inferiority margins: how they are chosen and how they are abused Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med , 2021) with…	+42	46	10k	5mo
Sample size calculations, read backwards from the published number intention to treat surrogate endpoints randomised trial Sample size calculations, read backwards from the published number Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl J Med , 2016). Please…		2	8.1k	6mo
How to read a forest plot, properly, from scratch randomised trial intention to treat surrogate endpoints estimand Solved The question in the title: How to read a forest plot, properly, from scratch I will give what I have already checked below so nobody repeats it. Session topic: STEP 4 ( JAMA , 2021). Please read it before…	+73	81	17k	7mo
Coming back to: Sample size calculations, read backwards from the published number estimand discontinuation & dropout surrogate endpoints randomised trial On the subject in the title: Sample size calculations, read backwards from the published number Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…	+82	88	1.8k	11mo
Comparators chosen for regulatory reasons rather than clinical ones — one year on randomised trial intention to treat open label estimand Solved Comparators chosen for regulatory reasons rather than clinical ones — one year on — setting out what I have, and where I think it stops being reliable. Session topic: SURMOUNT-2 ( Lancet , 2023). Please read…	+82	87	1.1k	12mo
Interim analyses and stopping rules — does this still hold? estimand discontinuation & dropout open label surrogate endpoints Solved Interim analyses and stopping rules — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SCALE ( N Engl J Med , 2015) with SURMOUNT-4 (…	+30	34	29k	13mo
Reading a trial's population section before its results — does this still hold? randomised trial open label intention to treat discontinuation & dropout Closed Reading a trial's population section before its results — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen STEP 1 ( N Engl J Med ,…	+140	154	5.4k	14mo
Comparators chosen for regulatory reasons rather than clinical ones surrogate endpoints open label estimand randomised trial Pinned Closed On the subject in the title: Comparators chosen for regulatory reasons rather than clinical ones Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…		2	27k	14mo
Follow-up: Open-label extensions: what survives and what does not open label intention to treat surrogate endpoints estimand Solved Open-label extensions: what survives and what does not — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURMOUNT-1 ( N Engl J Med , 2022) and…	+22	26	397	16mo
[2026 update] How to read a forest plot, properly, from scratch estimand discontinuation & dropout surrogate endpoints Solved How to read a forest plot, properly, from scratch — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA , 2024). Please read it before…	+49	53	643	19mo

Sponsored Janoshik Analytical — independent third-party testingHPLC purity and mass-spectrometric identity on submitted samples, reported with the method stated. The laboratory most often cited in this community’s verification records.Independent testing → Sponsored GL Biochem (Shanghai) Ltd. — synthesis, directFounded 1998. ISO 9001 and cGMP certified, over 1,500 staff and 200-plus patents. Custom peptide synthesis and amino acid derivatives, with a batch certificate on every order.Custom synthesis →